PROteolysis-Targeting Chimeras (PROTACs) represent a promising therapeutic approach by facilitating the degradation of target proteins via E3 ligase enzymes. Here, the authors analyze recent advances and challenges in cereblon-based PROTACs from synthesis to clinical trials, offering insights to guide future development in cereblon-based targeted protein degradation.
- André T. S. Vicente
- Sara P. S. P. Moura
- Jorge A. R. Salvador
